As a member of our CMC team, you will support and shape the development of innovative biopharmaceuticals, taking responsibility for the oversight of external analytical development activities at CDMOs and CROs for antibodies, small molecules, and antibody–drug conjugates (ADCs). You will work in a highly interdisciplinary environment with opportunities to continuously expand your technical expertise and adopt new analytical approaches.
-
Oversee outsourced analytical activities to ensure alignment with agreed timelines and deliverables.
-
Act as a scientific point of contact for external analytical laboratories, facilitating technical discussions.
-
Development, optimization, and maintenance of analytical methods for e.g. antibodies, small molecules and antibody–drug conjugates (ADCs) across different development stages.
-
Support the transfer of analytical methods to internal teams and external partners.
-
Participate in cross-functional project teams and provide regular progress updates during the CMC team meetings
-
Preparation, review, and organization of analytical documentation, including protocols, reports, and method descriptions.
-
Conduct literature research and lead continuous improvement projects.
At Tubulis, curiosity and innovation drive us to transform cancer treatment. We are a fast-growing biotech where science meets passion—and where you have the chance to grow with us.
Impact that matters: Contribute to breakthrough therapies.-
Global mindset: Work in an international, diverse team.
-
Grow & thrive: Develop your career in a supportive, fast-moving environment.
-
Innovation every day: Push boundaries with cutting-edge science.
At Tubulis, your ideas matter, your growth matters—and together, we make a difference.
Tubulis is a clinical stage biotech company that generates uniquely matched antibody-drug conjugates (ADCs) with superior biophysical properties that have demonstrated durable on-tumor delivery and long-lasting anti-tumor activity in preclinical models. We recently closed on a Series C fundraising round totaling €344M (US $401M).
The development of novel, effective and safe therapies for the treatment of cancer is one of the main challenges for modern medicine. We want to drive this process forward. The main goal of Tubulis is to become a leading company in the field of targeted therapeutics and ADCs. With a strong team, our own technologies and innovative therapeutic concepts, we are ushering in a new era in the ongoing fight against cancer and share the vision of helping patients world-wide. Be part of a multidisciplinary and focused team, that works towards getting novel promising ADCs to patients with solid and hematological cancers.
